Skip to content
ppharmaranks
Menu
Class ITerminated

Atovaquone Oral Suspension USP recall

FDA recall D-0444-2024 · initiated Mar 28, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Apr 24, 2024How we research

AvKARE recalled Atovaquone Oral Suspension USP in Mar 2024 — an FDA Class I recall (D-0444-2024) because Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.

Most serious — a reasonable probability that use will cause serious harm or death.

Why it was recalled

Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.

Sterility could not be assured

The maker could not guarantee the product was sterile. That matters most for injections and eye products, where a contaminated dose reaches past the body's defences.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot: AW0221A Exp. 08/30/2025

Quantity recalled: 153 cartons

Details

Product
Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.
Recalling company
AvKARE
Classification
Class I
Status
Terminated
Type
Voluntary: Firm initiated
Distribution
US Nationwide.
Initiated
Mar 28, 2024
FDA report date
Apr 24, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Atovaquone Oral Suspension USP recalled?
AvKARE recalled Atovaquone Oral Suspension USP in Mar 2024 — an FDA Class I recall (D-0444-2024) because Microbial contamination of a non-sterile product: potential Bacillus cereus contamination. Most serious — a reasonable probability that use will cause serious harm or death.
Why was Atovaquone Oral Suspension USP recalled?
Per the FDA enforcement record, the reason for recall D-0444-2024 was: Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.
Is a recalled Atovaquone Oral Suspension USP dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. Most serious — a reasonable probability that use will cause serious harm or death. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Atovaquone Oral Suspension USP are affected?
Distributed: US Nationwide.. The recall covers these lots — Lot: AW0221A Exp. 08/30/2025. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0444-2024.

Source: openFDA Drug Enforcement record D-0444-2024

← All drug recalls